科翔股份(300903.SZ):科翔鈉能計劃今年7月份建成鈉離子電池中試線並進行批量生產
格隆匯3月15日丨科翔股份(300903.SZ)在3月14日接受特定機構調研時表示,公司控股子公司科翔鈉能計劃今年7月份建成鈉離子電池中試線並進行批量生產,基於現在的市場、已有的潛在和意向客户,公司計劃分三步建立產能為6GWH的鈉離子電池生產線。
控股子公司富驊新能源主要做鈉離子電池正極材料,計劃今年建成2條生產線,同時建設3條生產線,由於生產線建成後需要調試,預計今年將產生2,000萬元收入;明年計劃進一步增加5條生產線,達到10條生產線;至2025年,若所有生產線全部滿產,將帶來10億元收入。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.